Lists of Vaccine Candidates:
* Vaccine Trackers: Bloomberg.com and CDC Vaccinations tracker
* Skeptical Raptor: Coronavirus vaccines – massive list of vaccine candidates for COVID-19
* Regulatory Affairs Professionals Society: COVID-19 Vaccine Tracker
* World Health Organization: Landscape of Covid-19 Candidate Vaccines (22 May 2020)
Latest Vaccine News:
27 July
* CNBC: Coronavirus vaccine from Oxford and AstraZeneca shows positive response in early trial
22 July 2020
* Doctor reinfected with COVID-19 — three months after recovering — Why is this in the Vaccine News section? Because the doctor had antibodies to the virus, and yet was reinfected. This suggests the possibility that a vaccine which provokes the immune system to make antibodies still might not protect us fully.
21 July 2020
* Possible but not certain COVID-19 vaccine rolled out this year: Oxford developer
20 July 2020
* AstraZeneca, Oxford Post Positive Phase I Data for COVID-19 Vaccine Candidate
15 July 2020
* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report Results: “The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.”
7 July 2020
* The Lancet journal Update on Vaccines
Is it ethical to challenge vaccinated volunteers by deliberate infection with Covid-19? Here are some articles discussing the topic:
* Science Mag articleSpeed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn
* Ethics and Human Research article: Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.
* Should scientists infect healthy people with the coronavirus to test vaccines?
* WHO: Key criteria for the ethical acceptability of COVID-19 human challenge studies (6 May 2020)
More Vaccine News
30 June 2020
* INOVIO Reports Positive Results for INO-4800 for Phase I COVID-19 Vaccine Trial
24 June 2020
* Vaccines Update: Oxford and Imperial College Vaccines by Dr. Mobeen Syed on his YouTube channel DrBeen’s Medical Lectures
22 June 2020
* Yahalom-Ronen, Yfat, et al. “A single dose of recombinant VSV-∆ G-spike vaccine provides protection against SARS-CoV-2 challenge.” bioRxiv (2020).
20 June 2020
* Berghea, Florian, et al. “Willingness to Pay for a for a Potential Vaccine Against SARS-CoV-2/COVID-19 Among Adult Persons.” (2020). Most persons are willing to pay in the range of 20 to 200 Euros or $22.50 to $225.00 U.S. dollars for a Covid-19 vaccine.
18 June 2020
* crushing sanctions Scientists worry ‘Operation Warp Speed’ is missing tried and true vaccines
16 June 2020
* The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2
11 June 2020
* Moderna on Thursday confirmed it plans to start a trial of 30,000 volunteers of its much-anticipated coronavirus vaccine in July as the company enters the final stage of testing.
8 June 2020
* Cell article on an inactivated SARS-CoV-2 vaccine candidate. Genetically stable and effective in animals.
3 June 2020
* MedCram - Coronavirus Pandemic Update 79: Five COVID-19 Vaccines to Keep an Eye On
2 June 2020
* 27% unlikely to be vaccinated against the coronavirus; Republicans, conservatives especially: POLL - The main opposition is from conservatives and middle age adults; 77% of seniors said they would get the vaccine. These numbers are interesting, a little troubling, but not too bad. A 70% vaccination rate is enough for herd immunity.
30 May 2020
* Yao, Dehui, et al. “Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2.” bioRxiv (2020).
29 May 2020
* Head of Pfizer pharmaceuticals says vaccine could be ready by October - “If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can… have a vaccine around the end of October,” he said.
27 May 2020
* Nature: Immunogenicity of a DNA vaccine candidate for COVID-19 - report on Inovio’s COVID-19 vaccine candidate, INO-4800. Read this TrialSiteNews Article
26 May 2020
* The Lancet: CanSino’s Phase I Vaccine is reported to be successful in this published study.
* Eyal, N. “Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.” Ethics & Human Research (2020).
* Novavax begins Phase I vaccine trial in Australia (Video)
25 May 2020
* NY Times: Novavax Coronavirus Vaccine Begins Human Testing “The phase 1 trial aims to test whether the vaccine is safe and triggers an immune response.”
* The Lancet: CanSino’s Phase I Vaccine is reported to be successful in this published study. It is a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine. The vaccine is non-contagious as the virus was altered to be “replication defective”. The Covid-19 RNA coding for a specific portion of its Spike protein was coded into the adenovirus’ DNA. The vaccine is injected into the muscle of a patient, and it causes the cells in the muscle to make the Spike protein. The immune system then recognizes the protein as foreign, and within 28 days produced antibodies to the receptor binding domain (RBD) of the Spike protein. Three doses of the vaccine were tested; all produced antibodies. The high-dose test was most successful, with 100% of patients producing antibodies.
20 May 2020
* Science magazine (AAAS) article details successful test of DNA vaccine on rhesus macaques.
19 May 2020
* Bad News: Doubts over Oxford vaccine as it fails to stop coronavirus in animal trials
* Good News: Early results from Moderna coronavirus vaccine trial show participants developed antibodies against the virus
* More Good News: Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE — “Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques”
18 May 2020
* Cai, Yujia, et al. “A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities.” bioRxiv (2020).
— “ShaCoVacc” incorporates spike-encoding mRNA inside, and decorating spike proteins on the surface of, the virus simulating particles (VSPs), which are derived from lentiviral particles.
* Moderna mRNA vaccine, Moderna’s COVID-19 vaccine shows positive results, moves to larger studies (NBC News)
* Two vaccines: one is a DNA plasmid vaccine; the other is a live-attenuated vaccine using a recombinant measles virus (rMV).
Two Indian companies in race for vaccine against Covid-19 (The Hindu Business Line)
Covid.us.org 